Eli Lilly (LLY) Stock Looks Undervalued Relative To Fair Value

Eli Lilly stock has delivered a very large 5 year return while valuation checks now give a more mixed read. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside compared with a share price that already embeds high expectations.

• Eli Lilly has returned about 362.3% over 5 years, which puts extra focus on whether current holders are paying a premium for that track record.
• Expectations around long term demand for its obesity and diabetes treatments can support higher cash flow assumptions. At the same time, concentration in a few key drug franchises may leave the valuation sensitive if those expectations are not met.
• The company scores 4 out of 6 on valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation, according to this assessment.

The issue now is whether Eli Lilly's current share price still leaves enough room above or below the intrinsic value estimate to make the recent rally look justified on valuation grounds.

Eli Lilly delivered 70.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is Eli Lilly a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Eli Lilly might be worth today based on projected future cash generation. For Eli Lilly, the latest twelve month free cash flow is about $13.6b, and the model applies a growing cash flow profile that reaches higher projected levels by 2030.

On these assumptions, the DCF points to an intrinsic value of about $1,688 per share, which is roughly 29.9% above the current share price and indicates the stock screens as potentially undervalued on this basis. The strong recent boost from obesity and diabetes drugs highlighted in Eli Lilly’s Q2 2026 earnings helps explain why investors are willing to ascribe rich multiples. At the same time, the DCF outcome indicates that the modeled cash flow outlook supports a value above the current market price.

Overall, this DCF view indicates Eli Lilly stock currently appears undervalued relative to its projected cash flows, based on the assumptions used in the model.

Our Discounted Cash Flow (DCF) analysis suggests Eli Lilly is undervalued by 29.9%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eli Lilly.

Is Eli Lilly Fairly Priced on Earnings?

The P/E ratio is a useful cross check for Eli Lilly because earnings are a key driver for large, profitable pharmaceutical groups. The stock currently trades on a P/E of about 39.5x, compared with an industry average of roughly 16.4x and a peer group average near 46.3x. That puts Eli Lilly at a clear premium to the broader pharmaceuticals sector, yet at a discount to similar large cap peers.

The fair P/E ratio implied by this framework is about 40.0x. That is very close to where Eli Lilly trades today, suggesting the current multiple already reflects its growth profile, profitability and risk mix without looking stretched or unusually cheap.

On the P/E multiple, Eli Lilly stock currently looks priced at roughly fair value.

See what the numbers say about this price — find out in our valuation breakdown.

The Eli Lilly Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Eli Lilly pick up where the valuation checks stop. They outline the specific assumptions on Eli Lilly's future growth, margins and earnings that would need to hold for the stock to be worth materially more or materially less than today's price. These Narratives are available on Simply Wall St's Community page. Where a single ratio or model gives one headline figure, these Narratives explain the future behind it so you can track whether that story continues to play out.

Eli Lilly attracts sharply different views right now, with some community members focused on GLP 1 upside and others flagging policy and concentration risks.

Bull case: roughly fairly valued

"The main growth driver, tirzepatide, is well protected for years to come, according to drug-patent data…"

Read the full Bull Case to see why Eli Lilly could be undervalued

Bear case: 32% overvalued

"Potential drug pricing reforms and wider pricing parity efforts threaten future profitability and limit pricing power, especially for high-profile obesity and diabetes products…"

Read the full Bear Case to see why Eli Lilly could be overvalued

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

The Bottom Line

Eli Lilly looks undervalued on the Discounted Cash Flow (DCF) intrinsic value estimate, which sits well above the current share price. The market multiple view is closer to about right, which implies the recent share price move already prices in a lot of the story. Together, these signals point to a stock that is no longer obviously cheap, yet not clearly overextended either. The key question from here is whether Eli Lilly can sustain the cash flow and earnings power implied by expectations for its obesity and diabetes portfolio, without concentration or policy risks eroding that outlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com